Cerenome, Inc. (CNSY)
NASDAQ: CNSY · Real-Time Price · USD
0.6427
-0.0272 (-4.06%)
At close: Nov 6, 2026, 4:00 PM EST
0.6651
+0.0224 (3.49%)
After-hours: Nov 6, 2026, 7:58 PM EST
Cerenome Revenue
Cerenome had revenue of $411.00K in the quarter ending June 30, 2026, a decrease of -70.43%. This brings the company's total for the last twelve months to $4.20M, down -20.95% year-over-year. In the year 2025, Cerenome had annual revenue of $5.21M, down -10.49%. That makes Cerenome the 40,559th largest company in the world by revenue and 5,404th in the United States.
Revenue (ttm)
$4.20M
Revenue Growth
-20.95%
P/S Ratio
1.16
Revenue / Employee
$150,107
Employees
28
Market Cap
4.88M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.21M | -611.00K | -10.49% |
| Dec 31, 2024 | 5.82M | 911.00K | 18.54% |
| Dec 31, 2023 | 4.91M | 4.69M | 2,093.30% |
| Dec 31, 2022 | 224.00K | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 303.00K | -6.70M | -95.67% |
| Dec 31, 2019 | 7.00M | 4.02M | 134.60% |
| Dec 31, 2018 | 2.98M | -739.00K | -19.85% |
| Dec 31, 2017 | 3.72M | -3.00M | -44.65% |
| Dec 31, 2016 | 6.72M | -97.00K | -1.42% |
| Dec 31, 2015 | 6.82M | 4.18M | 157.88% |
| Dec 31, 2014 | 2.65M | -2.43M | -47.87% |
| Dec 31, 2013 | 5.07M | -718.00K | -12.40% |
| Dec 31, 2012 | 5.79M | 3.78M | 187.73% |
| Dec 31, 2011 | 2.01M | -360.00K | -15.17% |
| Dec 31, 2010 | 2.37M | -6.52M | -73.32% |
| Dec 31, 2009 | 8.89M | 6.57M | 282.49% |
| Dec 31, 2008 | 2.33M | -2.93M | -55.77% |
| Dec 31, 2007 | 5.26M | -1.22M | -18.82% |
| Dec 31, 2006 | 6.48M | 6.11M | 1,645.55% |
| Dec 31, 2005 | 371.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Evogene | 1.66M |
| Can-Fite BioPharma | 405.00K |
| AIM ImmunoTech | 95.00K |
| Senti Biosciences Holdings | 55.00K |
| Cardio Diagnostics Holdings | 15.19K |
| Azitra | 7.50K |
| Pulmatrix | 3.00K |
| Alaunos Therapeutics | 3.00K |
CNSY News
- 4 days ago - Cerenome Secures National In-Network Agreement with Aetna for CNSide® - GlobeNewsWire
- 10 days ago - Cerenome completes enrollment in ReSPECT-GBM study - TheFly
- 10 days ago - Cerenome Completes Enrollment in Phase 2 ReSPECT-GBM Trial of REYOBIQ™ in Recurrent Glioblastoma - GlobeNewsWire
- 12 days ago - Cerenome to Present Interim Clinical Update on the ReSPECT-LM Trial of Multiple REYOBIQ™ Doses in Leptomeningeal Metastases - GlobeNewsWire
- 18 days ago - Cerenome announces new dual mechanism of action for REYOBIQ - TheFly
- 18 days ago - Cerenome Announces New Dual Mechanism of Action Featuring Lethal DNA Damage and Beneficial Immunomodulation Supporting Lead Investigational Drug REYOBIQ™ - GlobeNewsWire
- 4 weeks ago - Cerenome Secures In-Network Agreement with Florida Blue for CNSide® CSF Tumor Cell Enumeration and Molecular Profile Tests - GlobeNewsWire
- 4 weeks ago - Cerenome Launches CNSide® CSF Molecular Profile Tests - GlobeNewsWire